Epigenetic study provides new approaches to combination therapies for aggressive cancers

(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) A recent study by CeMM reveals how the interaction of the epigenetic protein BRD4 with the metabolic enzyme MTHFD1 controls gene expression and cell proliferation. The results of the study have now been published in the renowned journal Nature Genetics. They suggest novel approaches for the development of combination therapies for aggressive cancers.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news